Emergent BioSolutions Inc.
EBS· NYSE
EBSEmergent BioSolutions Inc.
Filed Feb 27, 2026 · 10-K · 58 days after period end · 0001367644-26-000015
derived · Computed from the longer spans the company filed.
| Metric | Q4 2025dderived from reported figures | Q4 2024dderived from reported figures | Q4 2023dderived from reported figures | Q4 2022 |
|---|---|---|---|---|
| Revenue | $148.70M | $194.70M | $276.60M | $330.20M |
| Net Income | -$54.60M | -$31.30M | -$49.50M | -$67.00M |
| EPS Diluted | — | — |
Emergent BioSolutions Inc. · CIK 1367644 · Engraved from SEC EDGAR
| — |
| -$1.34 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
ended Dec 31, 2025 · filed Feb 27, 2026 · 58 d after period end
